Welcome to the international HTA database

Showing [23368 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Allogeneic T cells (high-risk haematological malignancies) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018	NIHR Health Technology Assessment programme	A pedometer-based walking intervention in 45- to 75-year-olds, with and without practice nurse support: the PACE-UP three-arm cluster RCT
2018	Institut national d'excellence en sante et en services sociaux (INESSS)	[Optimal use guide: antibiotic prophylaxis during clean orthopedic surgery in children and adults]
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Global postural re-education (RPG®) in spine conditions]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (HIV-infected children) - Benefit assessment according to §35a Social Code Book V]
2018	NIHR Health Technology Assessment programme	Screening women aged 65 years or over for abdominal aortic aneurysm: a modelling study and health economic evaluation
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Gait laboratory in patients with gait disorders]
2018	Canary Health Service	[Safety, effectiveness, and cost-effectiveness of subcutaneous implantable cardioverter-defibrillator in primary and secondary prevention of sudden cardiac death]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Colorectal cancer screening in persons with a relevant family history - Update to commission S11-01]
2018	NIHR Health Technology Assessment programme	Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study
2018	NIHR Health Technology Assessment programme	Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study
2018	NIHR Health Technology Assessment programme	Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Riluzole in amyotrophic lateral sclerosis]
2018	Canary Health Service	[Cost-effectiveness of vaccination against herpes zoster]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ultrasound-guided high-intensity focused ultrasound for malignant neoplasms of the pancreas - second Addendum to Commission H16-02C]
2018	NIHR Health Technology Assessment programme	Computerised interpretation of the fetal heart rate during labour: a randomised controlled trial (INFANT)
2018	NIHR Health Technology Assessment programme	Therapeutic hypothermia to reduce intracranial pressure after traumatic brain injury: the Eurotherm3235 RCT
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Alemtuzumab in multiple sclerosis]
2018	Canary Health Service	[Nutritional treatment of adults with chronic kidney disease (CKD) and irreversible severe energy-protein malnutrition using ordinary food]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ocrelizumab (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2018	NIHR Health Technology Assessment programme	Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Immunoglobulin in chronic inflammatory demyelinating polyneuropathy and other neurological conditions]
2018	Canadian Agency for Drugs and Technologies in Health (CADTH)	Interventions for temporomandibular joint disorder: an overview of systematic reviews
2018	Canary Health Service	[Epidermal growth factor for the treatment of diabetic foot ulcers]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lumacaftor/ivacaftor (cystic fibrosis) - Benefit assessment according to §35a Social Code Book V]
2017	NIHR Health Technology Assessment programme	A randomised controlled study of the effectiveness of breathing retraining exercises taught by a physiotherapist either by instructional DVD or in face-to-face sessions in the management of asthma in adults
2017	National Institute for Health and Care Excellence (NICE)	Elotuzumab for previously treated multiple myeloma (terminated appraisal). NICE technology appraisal guidance 434
2017	NIHR Health Technology Assessment programme	Clinical effectiveness and cost-effectiveness of surgical options for the management of anterior and/or posterior vaginal wall prolapse: two randomised controlled trials within a comprehensive cohort study results from the PROSPECT Study
2017	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Occupational chemical exposures and cardiovascular disease]
2017	National Institute for Health and Care Excellence (NICE)	Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal). NICE technology appraisal guidance 435
2017	National Institute for Health and Care Excellence (NICE)	Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 436
2017	NIHR Health Technology Assessment programme	A multicentre, randomised controlled trial of position during the late stages of labour in nulliparous women with an epidural: clinical effectiveness and an economic evaluation (BUMPES)
2017	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Treatment options of arm fractures in the elderly]
2017	National Institute for Health and Care Excellence (NICE)	Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal). NICE technology appraisal guidance 437
2017	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Interventions to improve foster children’s mental and physical health]
2017	National Institute for Health and Care Excellence (NICE)	Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 438
2017	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Endobronchial valves for the treatment of emphysema bullae.
2017	National Institute for Health and Care Excellence (NICE)	Cetuximab and panitumumab for previously untreated metastatic colorectal cancer. NICE technology appraisal guidance 439
2017	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Barricaid prosthesis for partial annulus replacement
2017	National Institute for Health and Care Excellence (NICE)	Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine. NICE technology appraisal guidance 440
2017	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Endovascular arteriovenous fistula creation systems
2017	National Institute for Health and Care Excellence (NICE)	Ixekizumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 442
2017	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	STAR tumour ablation system
2017	National Institute for Health and Care Excellence (NICE)	Obeticholic acid for treating primary biliary cholangitis. NICE technology appraisal guidance 443
2017	NIHR Health Technology Assessment programme	Effectiveness and cost effectiveness of cognitive behaviour therapy and short-term psychoanalytic psychotherapy compared with brief psychosocial intervention in the maintenance of symptomatic remission in adolescents with unipolar major depression (IMPACT): a randomised controlled trial
2017	National Institute for Health and Care Excellence (NICE)	Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 444
2017	National Institute for Health and Care Excellence (NICE)	Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 445
2017	National Institute for Health and Care Excellence (NICE)	Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia. NICE technology appraisal guidance 450
2017	National Institute for Health and Care Excellence (NICE)	Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia. NICE technology appraisal guidance 451
2017	National Institute for Health and Care Excellence (NICE)	Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal). NICE technology appraisal guidance 452
2017	NIHR Health Technology Assessment programme	Support and Assessment for Fall Emergency Referrals (SAFER) 2: a cluster randomised trial and systematic review of clinical effectiveness and cost-effectiveness of new protocols for emergency ambulance paramedics to assess older people following a fall with referral to community-based care when appropriate
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Angiogenesis inhibitors (bevacizumab - ranibizumab) in neovascular glaucoma and corneal neovascularization]
2017	National Institute for Health and Care Excellence (NICE)	Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal). NICE technology appraisal guidance 453
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Bariatric surgery as treatment for obesity in subjects over 65 years old]
2017	National Institute for Health and Care Excellence (NICE)	Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 454
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	Bariatric surgery to treat obesity in individuals under 21 years old
2017	HAYES, Inc.	Dorsal root ganglion stimulation for the treatment of complex regional pain syndrome
2017	National Institute for Health and Care Excellence (NICE)	Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people. NICE technology appraisal guidance 455
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Usefulness of N-terminal type B natriuretic propeptide in amyloidosis]
2017	HAYES, Inc.	Flexitouch system (Tactile Systems Technology Inc.) for lymphedema
2017	National Institute for Health and Care Excellence (NICE)	Ustekinumab for moderately to severely active Crohn's disease after previous treatment. NICE technology appraisal guidance 456
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Dynamic magnetic resonance imaging in pelvic floor dysfunction]
2017	HAYES, Inc.	Glucagon-like peptide-1 receptor agonists for the treatment of obesity in women with polycystic ovary syndrome
2017	National Institute for Health and Care Excellence (NICE)	Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane. NICE technology appraisal guidance 458
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Reducing mammaplasty for the treatment of patients with breast hypertrophy and chronic dorsalgia]
2017	HAYES, Inc.	iFuse Implant System (SI-Bone Inc.) for sacroiliac joint fusion for treatment of sacroiliac joint dysfunction
2017	National Institute for Health and Care Excellence (NICE)	Adalimumab and dexamethasone for treating non-infectious uveitis. NICE technology appraisal guidance 460
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Arterial stiffness measurement for cardiovascular risk classification in high blood pressure patients]
2017	HAYES, Inc.	Gore cardioform septal occluder (W.L. Gore & Associates) for closure of atrial septal defects
2017	National Institute for Health and Care Excellence (NICE)	Roflumilast for treating chronic obstructive pulmonary disease. NICE technology appraisal guidance 461
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Intrathecal opioid infusion pump for chronic cancer and non-cancer pain]
2017	HAYES, Inc.	Impella 2.5 System (Abiomed Inc.) for cardiac support in patients undergoing high-risk percutaneous coronary intervention
2017	National Institute for Health and Care Excellence (NICE)	Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma. NICE technology appraisal guidance 462
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Nonmydriatic stereoscopic retinal imaging for retinal condition]
2017	HAYES, Inc.	Intravenous immunoglobulin for treatment of intractable epilepsy in pediatric patients
2017	National Institute for Health and Care Excellence (NICE)	Bisphosphonates for treating osteoporosis. NICE technology appraisal guidance 464
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Transbronchial lung cryobiopsy in diffuse interstitial lung disease diagnosis]
2017	HAYES, Inc.	Ketamine infusion for treatment-resistant bipolar depression
2017	National Institute for Health and Care Excellence (NICE)	Baricitinib for moderate to severe rheumatoid arthritis. NICE technology appraisal guidance 466
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Cryoablation for the treatment of persistent or symptomatic paroxysmal atrial fibrillation]
2017	HAYES, Inc.	Micra transcatheter pacing system (Medtronic Inc.) for single-chamber pacemaker indications
2017	National Institute for Health and Care Excellence (NICE)	Holoclar for treating limbal stem cell deficiency after eye burns. NICE technology appraisal guidance 467
2017	NIHR Health Technology Assessment programme	The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysis
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	Biofeedback for women with urinary, fecal or combined incontinence
2017	HAYES, Inc.	Ocrelizumab (Ocrevus; Genentech Inc.) for primary progressive and relapsing-remitting multiple sclerosis
2017	National Institute for Health and Care Excellence (NICE)	Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal). NICE technology appraisal guidance 468
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Pomalidomide for relapsed and refractory myeloma]
2017	HAYES, Inc.	Radiofrequency nerve ablation for treatment of plantar fasciitis
2017	National Institute for Health and Care Excellence (NICE)	Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal). NICE technology appraisal guidance 469
2017	NIHR Public Health Research (PHR) programme	Evaluation of the impacts on health of the proposed UK industry levy on sugar sweetened beverages: developing a systems map and data platform, and collection of baseline and early impact data
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Epidermal growth factor (Heberprot-P®) in chronic ulcers]
2017	HAYES, Inc.	Raindrop near vision inlay (ReVision Optics Inc.) for presbyopia
2017	National Institute for Health and Care Excellence (NICE)	Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck. NICE technology appraisal guidance 473
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Biological agents and tofacitinib in rheumatoid arthritis]
2017	HAYES, Inc.	Teduglutide (Gattex; Shire-NPS Pharmaceuticals Inc.) to reduce parenteral support requirements in adults with short bowel syndrome
2017	National Institute for Health and Care Excellence (NICE)	Sorafenib for treating advanced hepatocellular carcinoma. NICE technology appraisal guidance 474
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Stiripentol for the treatment of severe myoclonic epilepsy in infants (Dravet's syndrome)]
2017	HAYES, Inc.	Urolift system (NeoTract Inc.) for treatment of benign prostatic hyperplasia
2017	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: beta-lactam allergies, assessment of the risk of cross-reactivity with cephalosporins and carbapenems in penicillin-allergic patients]
2017	National Institute for Health and Care Excellence (NICE)	Dimethyl fumarate for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 475